Trial reportJournal of nuclear medicine : official publication, Society of Nuclear Medicine2012
11C-Acetate PET/CT in localized prostate cancer: a study with MRI and histopathologic correlation.
Trial report in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00924313 (A Pilot Study of 11C-Acetate Positron Emission Tomography), which is not on this map. Cited by 47 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Pilot Study of 11C-Acetate Positron Emission Tomography (PET) and 3 Telsa Magnetic Resonance Imaging (MRI) in Men With Prostate Cancer Undergoing Prostatectomy
Who cites it
47 citing papers in PubMed, 2 syntheses or guidelines pooled it, 118 citations in OpenAlex.
- Radiopharmaceuticals for PET and SPECT Imaging: A Literature Review over the Last Decade.International journal of molecular sciences · 2022Pooled it
- [Focus on molecular imaging in prostate cancer].Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologiePooled it
- Prospective evaluation ofEuropean journal of nuclear medicine and molecular imaging · 2018Trial
- 18F-DCFBC Prostate-Specific Membrane Antigen-Targeted PET/CT Imaging in Localized Prostate Cancer: Correlation With Multiparametric MRI and Histopathology.Clinical nuclear medicine · 2017Trial
- Comparison of Prostate-Specific Membrane Antigen-Based 18F-DCFBC PET/CT to Conventional Imaging Modalities for Detection of Hormone-Naïve and Castration-Resistant Metastatic Prostate Cancer.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2016Trial
- (11)C-acetate as a new biomarker for PET/CT in patients with multiple myeloma: initial staging and postinduction response assessment.European journal of nuclear medicine and molecular imaging · 2014Trial
- Prognostic Value of Next-Generation Flow Cytometry Versus Dual-Tracer PET/CT for Minimal Residual Disease Assessment in Multiple Myeloma.Cancer medicine · 2026Article
- Acetate Metabolism in Urological Health and Disease.Serican journal of medicine · 2024Article
- Collagen-Specific Molecular Magnetic Resonance Imaging of Prostate Cancer.International journal of molecular sciences · 2022Article
- Molecular Imaging in Primary Staging of Prostate Cancer Patients: Current Aspects and Future Trends.Cancers · 2021Review
- A review on immunohistochemical and histopathologic validation in PET-CT findings with consideration to microRNAs.Medicine and pharmacy reports · 2019Review
- Biological principles and clinical application of positron emission tomography-tracers in prostate cancer: a review.Prostate international · 2019Review
- Molecular imaging of prostate cancer.The British journal of radiology · 2018Review
- Advances in medical imaging for the diagnosis and management of common genitourinary cancers.Urologic oncology · 2017Review
- Multimodal Imaging in Focal Therapy Planning and Assessment in Primary Prostate Cancer.Clinical and translational imaging · 2017Article
- Positron emission tomography (PET) in primary prostate cancer staging and risk assessment.Translational andrology and urology · 2017Review
- Molecular imaging and fusion targeted biopsy of the prostate.Clinical and translational imaging · 2017Article
- Performance characteristics and relationship of PSA value/kinetics on carbon-11 acetate PET/CT imaging in biochemical relapse of prostate cancer.American journal of nuclear medicine and molecular imaging · 2017Article
- Multiparametric [11C]Acetate positron emission tomography-magnetic resonance imaging in the assessment and staging of prostate cancer.PloS one · 2017Article
- The metabolic fate of acetate in cancer.Nature reviews. Cancer · 2016Review
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
19 authors at 1 institution in 1 country.
Funding
Abstract
unlabelledThis work characterizes the uptake of (11)C-acetate in prostate cancer (PCa), benign prostate hyperplasia, and normal prostate tissue in comparison with multiparametric MRI, whole-mount histopathology, and clinical markers to evaluate the potential utility of (11)C-acetate for delineating intraprostatic tumors in a population of patients with localized PCa.
methodsThirty-nine men with presumed localized PCa underwent dynamic-static abdominal-pelvic (11)C-acetate PET/CT for 30 min and 3-T multiparametric MRI before prostatectomy. PET/CT images were registered to MR images using pelvic bones for initial rotation-translation, followed by manual adjustments to account for prostate motion and deformation from the MRI endorectal coil. Whole-mount pathology specimens were sectioned using an MRI-based patient-specific mold resulting in improved registration between the MRI, PET, and pathology. (11)C-acetate PET standardized uptake values were compared with multiparametric MRI and pathology.
results(11)C-acetate uptake was rapid but reversible, peaking at 3-5 min after injection and reaching a relative plateau at approximately 10 min. The average maximum standardized uptake value (10-12 min) of tumors was significantly higher than that of normal prostate tissue (4.4 ± 2.05 [range, 1.8-9.2] vs. 2.1 ± 0.94 [range, 0.7-3.4], respectively; P < 0.001); however, it was not significantly different from that of benign prostatic hyperplasia (4.8 ± 2.01 [range, 1.8-8.8]). A sector-based comparison with histopathology, including all tumors greater than 0.5 cm, revealed a sensitivity and specificity of 61.6% and 80.0%, respectively, for (11)C-acetate PET/CT and 82.3% and 95.1%, respectively, for MRI. The (11)C-acetate accuracy was comparable to that of MRI when only tumors greater than 0.9 cm were considered. In a small cohort (n = 9), (11)C-acetate uptake was independent of fatty acid synthase expression using immunohistochemistry.
conclusion(11)C-acetate PET/CT demonstrates higher uptake in tumor foci than in normal prostate tissue; however, (11)C-acetate uptake in tumors is similar to that in benign prostate hyperplasia nodules. Although (11)C-acetate PET/CT is not likely to have utility as an independent modality for evaluation of localized PCa, the high uptake in tumors may make it useful for monitoring focal therapy when tissue damage after therapy may limit anatomic imaging methods.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.